AR124163A2 - A LYOPHILIZED ARIPIPRAZOLE COMPOSITION - Google Patents
A LYOPHILIZED ARIPIPRAZOLE COMPOSITIONInfo
- Publication number
- AR124163A2 AR124163A2 ARP210103281A ARP210103281A AR124163A2 AR 124163 A2 AR124163 A2 AR 124163A2 AR P210103281 A ARP210103281 A AR P210103281A AR P210103281 A ARP210103281 A AR P210103281A AR 124163 A2 AR124163 A2 AR 124163A2
- Authority
- AR
- Argentina
- Prior art keywords
- aripiprazole
- lyophilized
- composition
- water
- present
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 8
- 229960004372 aripiprazole Drugs 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000843 powder Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un objeto de la presente invención consiste en proveer una composición de aripiprazol liofilizada en polvo, que denota buena dispersabilidad y que se dispersa fácilmente en una suspensión homogénea cuando se reconstituye con agua. La presente invención provee una composición de aripiprazol liofilizada obtenida mediante un proceso que comprende los pasos de pulverización, con el fin de congelar una suspensión de aripiprazol que contiene (I) aripiprazol, (II) un vehículo para el aripiprazol y (III) agua para inyección, y secado, que comprende aripiprazol y un vehículo para el aripiprazol y está en forma de un polvo, siendo las partículas del polvo esféricas y porosas.An object of the present invention is to provide a powdery lyophilized aripiprazole composition, which exhibits good dispersibility and is easily dispersed into a homogeneous suspension when reconstituted with water. The present invention provides a lyophilized aripiprazole composition obtained by a process comprising the steps of spraying, in order to freeze a suspension of aripiprazole containing (I) aripiprazole, (II) a vehicle for aripiprazole and (III) water for injection, and drying, which comprises aripiprazole and a carrier for aripiprazole and is in the form of a powder, the powder particles being spherical and porous.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494088P | 2011-06-07 | 2011-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124163A2 true AR124163A2 (en) | 2023-02-22 |
Family
ID=46420491
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101990A AR086682A1 (en) | 2011-06-07 | 2012-06-06 | FORMULATION OF LIOFILIZED ARIPIPRAZOL |
| ARP210103281A AR124163A2 (en) | 2011-06-07 | 2021-11-29 | A LYOPHILIZED ARIPIPRAZOLE COMPOSITION |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101990A AR086682A1 (en) | 2011-06-07 | 2012-06-06 | FORMULATION OF LIOFILIZED ARIPIPRAZOL |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11154507B2 (en) |
| EP (1) | EP2717859B1 (en) |
| JP (1) | JP6012637B2 (en) |
| KR (1) | KR102014124B1 (en) |
| CN (3) | CN108379231A (en) |
| AR (2) | AR086682A1 (en) |
| AU (1) | AU2012267810B2 (en) |
| BR (1) | BR112013031459B1 (en) |
| CA (1) | CA2837693C (en) |
| CO (1) | CO6842019A2 (en) |
| CY (1) | CY1118561T1 (en) |
| DK (1) | DK2717859T3 (en) |
| EA (1) | EA023951B1 (en) |
| ES (1) | ES2599479T3 (en) |
| HK (1) | HK1191245A1 (en) |
| HR (1) | HRP20161357T1 (en) |
| HU (1) | HUE031723T2 (en) |
| IL (1) | IL229467A (en) |
| JO (1) | JO3410B1 (en) |
| LT (1) | LT2717859T (en) |
| MX (1) | MX354473B (en) |
| MY (1) | MY166052A (en) |
| PL (1) | PL2717859T3 (en) |
| PT (1) | PT2717859T (en) |
| SG (1) | SG195046A1 (en) |
| SI (1) | SI2717859T1 (en) |
| TW (1) | TWI519320B (en) |
| UA (1) | UA112186C2 (en) |
| WO (1) | WO2012169662A1 (en) |
| ZA (1) | ZA201308868B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (en) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | Injectable preparation |
| MD3362066T2 (en) * | 2015-10-15 | 2022-08-31 | Les Laboratoires Servier Sas | Combination therapy for treating malignancies |
| CN105663057A (en) * | 2015-12-30 | 2016-06-15 | 中国药科大学 | Aripiprazole long-acting suspension and preparation method thereof |
| AU2017303975A1 (en) | 2016-07-28 | 2019-03-21 | Mylan Laboratories Ltd, | Process for preparing sterile aripiprazole formulation |
| WO2021233402A1 (en) * | 2020-05-21 | 2021-11-25 | 江苏先声药业有限公司 | Brexpiprazole-containing pharmaceutical composition and preparation method therefor |
| CN112656767A (en) * | 2021-01-22 | 2021-04-16 | 烟台东诚药业集团股份有限公司 | Enoxaparin sodium injection and preparation method thereof |
| EP4043008A1 (en) | 2021-02-15 | 2022-08-17 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Method for the preparation of a pharmaceutical composition comprising aripiprazole |
| WO2023083212A1 (en) * | 2021-11-10 | 2023-05-19 | 广东东阳光药业有限公司 | Quinoline pharmaceutical composition |
| GR1010656B (en) * | 2023-03-23 | 2024-03-21 | Φαρματεν Α.Β.Ε.Ε., | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the prepatation thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| GB9105705D0 (en) | 1991-03-18 | 1991-05-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| DK0729357T3 (en) | 1993-11-19 | 2005-06-06 | Janssen Pharmaceutica Nv | Microencapsulated 1,2-benzazoles |
| GB9718986D0 (en) | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| MY129350A (en) | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| AR033485A1 (en) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME |
| US20050019607A1 (en) | 2003-06-30 | 2005-01-27 | Franky So | OLED device with mixed emissive layer |
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| ZA200602347B (en) * | 2003-10-23 | 2007-09-26 | Otsuka Pharma Co Ltd | Controlled release sterile injectable aripiprazole formulation and method |
| EP1732107A4 (en) | 2004-03-30 | 2009-05-13 | Fujitsu Microelectronics Ltd | Method for correcting electron beam exposure data |
| US7731873B2 (en) | 2005-08-09 | 2010-06-08 | Coopervision International Holding Company, Lp | Contact lens mold assemblies and systems and methods of producing same |
| EP2279727A3 (en) * | 2005-09-15 | 2011-10-05 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
| UA97286C2 (en) * | 2007-07-31 | 2012-01-25 | Оцука Фармасьютикал Ко., Лтд. | Method for producing an aripiprazole suspension and freeze-dried formulation |
-
2012
- 2012-06-03 JO JOP/2012/0141A patent/JO3410B1/en active
- 2012-06-06 TW TW101120275A patent/TWI519320B/en active
- 2012-06-06 AR ARP120101990A patent/AR086682A1/en not_active Application Discontinuation
- 2012-06-07 PT PT127311892T patent/PT2717859T/en unknown
- 2012-06-07 US US14/124,459 patent/US11154507B2/en active Active
- 2012-06-07 JP JP2013554727A patent/JP6012637B2/en active Active
- 2012-06-07 MX MX2013014186A patent/MX354473B/en active IP Right Grant
- 2012-06-07 MY MYPI2013702194A patent/MY166052A/en unknown
- 2012-06-07 LT LTEP12731189.2T patent/LT2717859T/en unknown
- 2012-06-07 CN CN201810450421.2A patent/CN108379231A/en active Pending
- 2012-06-07 CN CN201610937357.1A patent/CN106389357A/en active Pending
- 2012-06-07 CN CN201280027909.5A patent/CN103596557A/en active Pending
- 2012-06-07 SG SG2013085568A patent/SG195046A1/en unknown
- 2012-06-07 BR BR112013031459-1A patent/BR112013031459B1/en active IP Right Grant
- 2012-06-07 ES ES12731189.2T patent/ES2599479T3/en active Active
- 2012-06-07 AU AU2012267810A patent/AU2012267810B2/en active Active
- 2012-06-07 KR KR1020147000021A patent/KR102014124B1/en active IP Right Grant
- 2012-06-07 CA CA2837693A patent/CA2837693C/en active Active
- 2012-06-07 EA EA201391818A patent/EA023951B1/en not_active IP Right Cessation
- 2012-06-07 PL PL12731189T patent/PL2717859T3/en unknown
- 2012-06-07 DK DK12731189.2T patent/DK2717859T3/en active
- 2012-06-07 EP EP12731189.2A patent/EP2717859B1/en active Active
- 2012-06-07 SI SI201230741A patent/SI2717859T1/en unknown
- 2012-06-07 HU HUE12731189A patent/HUE031723T2/en unknown
- 2012-06-07 WO PCT/JP2012/065180 patent/WO2012169662A1/en active Application Filing
- 2012-07-06 UA UAA201315553A patent/UA112186C2/en unknown
-
2013
- 2013-11-17 IL IL229467A patent/IL229467A/en active IP Right Grant
- 2013-11-19 ZA ZA2013/08868A patent/ZA201308868B/en unknown
- 2013-12-30 CO CO13302836A patent/CO6842019A2/en unknown
-
2014
- 2014-05-14 HK HK14104543.8A patent/HK1191245A1/en unknown
-
2016
- 2016-10-18 HR HRP20161357TT patent/HRP20161357T1/en unknown
- 2016-11-03 CY CY20161101125T patent/CY1118561T1/en unknown
-
2021
- 2021-09-24 US US17/448,862 patent/US20220008341A1/en not_active Abandoned
- 2021-11-29 AR ARP210103281A patent/AR124163A2/en unknown
-
2023
- 2023-10-09 US US18/483,098 patent/US20240041774A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124163A2 (en) | A LYOPHILIZED ARIPIPRAZOLE COMPOSITION | |
| BR112014014323A2 (en) | use of polymeric excipients for freeze drying or particle freezing | |
| BR112015004418A2 (en) | Inhalable dry powder composition, drug release system, particle forming process and kit. | |
| BR112015022855A2 (en) | compositions and method for producing an in vitro antibody | |
| MX2015001958A (en) | Improved compositions of substantially spherical particles. | |
| MX2015006935A (en) | Soluble pouch comprising hueing dye. | |
| BR112015028853A2 (en) | DETERGENT COMPOSITION WITH LOW PH | |
| BR112014029026A2 (en) | surface modified hybrid carbon particles, production methods and applications thereof | |
| EP3082840A4 (en) | Methods and assays relating to circulating tumor cells | |
| WO2012140274A3 (en) | Agonists and antagonists of the wnt pathway | |
| WO2014047496A3 (en) | Spray drying microcapsules | |
| CL2017001836A1 (en) | A fertilizer composition and the method of its use. | |
| MX2013008903A (en) | Methods of developing terpene synthase variants. | |
| CL2011001296A1 (en) | Monoclonal antibody capable of inhibiting cmet dimerization; nucleic acid, vector and host cell comprising the sequences encoding the antibody; composition comprising the antibody; use of the antibody to inhibit the growth and / or proliferation of tumor cells. | |
| BR112013028449A2 (en) | compositions comprising hydrogel particles | |
| WO2014199352A3 (en) | Lipid-based platinum-n-heterocyclic carbene compounds and nanoparticles | |
| EP3083658A4 (en) | Methods and assays relating to circulating tumor cells | |
| MX2013008062A (en) | Gel-encapsulated microcolony screening. | |
| JOP20130342B1 (en) | A stabilized pemetrexed formulation | |
| WO2014086982A3 (en) | Stable metal compounds, their compositions and methods of their use | |
| SMT201500320B (en) | LYOPHILIZATION OF TENSIOACTIVE AGENT PYLONOMIC SYNTHETIC LYMPHOMOMA | |
| UY33308A (en) | PRODUCTION OF HIGH DENSITY UNIFIED COMPOSITIONS | |
| MX2015008302A (en) | Low density coated animal litter compositions. | |
| EP2931311A4 (en) | Lyophilized spherical pellets of anti-il-23 antibodies | |
| IL229176B (en) | Cryopreserved, thawed and reactivated t cell containing compositions, methods of producing same and use of same in immunotherapy” |